Senior Medical Science Liaison; Neurology); West Region

We are developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH
103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH
212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. Our newest candidate, DNTH
312, is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. DNTH
312 aims to be Phase 1 ready by year end 2027. To learn more, please visit  and follow us on Linked In.

We are developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead antibody, claseprubart (DNTH
103), is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein that drives disease pathology – enabling less frequent and more convenient self-administered subcutaneous injections. Our second clinical candidate, DNTH
212 is a first and potentially best in class, bifunctional inhibitor that targets clinically validated and complementary disease modifying mechanisms, Type 1 IFN suppression and B cell modulation – enabling potential for improved clinical outcomes and patient friendly convenient, self-administered subcutaneous injections. Our newest candidate, DNTH
312, is an internally developed, investigational, first-in-class, next-generation bifunctional fusion protein combining claseprubart and TACI to target potent inhibition of aC1s and BAFF/APRIL. DNTH
312 aims to be Phase 1 ready by year end 2027. To learn more, please visit  and follow us on Linked In.

Dianthus Therapeutics is seeking a Senior Medical Science Liaison (MSL) to support the advancement of our neuromuscular disease portfolio, including myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN). This field-based role will build strategic relationships with key opinion leaders, investigators, healthcare professionals, and advocacy organizations while serving as a scientific expert and trusted partner. The Senior MSL will generate actionable insights, support clinical development and evidence generation activities, and contribute to future launch readiness efforts across the portfolio.

We are building a culture of individuals who hold our core principles at the center of our operations, with the goal to elevate the care of our patients' lives. We are open to you working remotely.

• Serve as the scientific expert for Dianthus' neuromuscular disease programs and maintain strong relationships with key external stakeholders.
• Conduct compliant scientific exchange regarding disease state education, clinical data, unmet needs, and investigational therapies.
• Gather and communicate medical insights to inform Medical Affairs, Clinical Development, and future commercialization strategies.
• Support clinical trials through investigator engagement, site identification, enrollment support, and protocol discussions as requested.
• Represent Dianthus at scientific congresses, advisory boards, investigator meetings, and other external medical forums.
• Contr…